BioNTech shares fell 1.2% in premarket trading after BMO downgraded the stock and cut its price target from $128 to $105, citing declining vaccine demand and the termination of a cancer vaccine trial.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Source:Yahoo财经 · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
U.S. Treasury Sanctions Chinese-Language Cyber-Scam Hub Xinbi Guarantee
-
2
24/7 Wall St. Initiates Marvell Technology (MRVL) with Buy Rating, Sets Price Target at $281.53
-
3
MOL Chairman: Violent Yen Fluctuations Could Lead to Global Market "Chaos," Outlook for Strait of Hormuz Shipping Recovery Pessimistic
-
4
Chinese energy firms, including Sungrow and EVE Energy, warn policy volatility complicates long-term overseas expansion amid geopolitical risks
-
5
Token Unlocks: Mechanism and Market Impact Analysis
-
6
Donald Trump threatens to restrict sales of Canada's Bombardier aircraft in the U.S., as Canada imposes retaliatory tariffs on American products.
-
7
US-Iran Conflict Escalates: Iran Claims Attacks on US Vessels and Oil Tankers, Brent Crude Nears $100/Barrel
-
8
PALLA Coin Analysis: Market Activity and Restricted Trading Channels
-
9
LKN Coin Analysis: LinkCoin Token and Lockness Project Status and Trading Overview
-
10
MetaWear (WEAR) Token: Current Status Analysis and Future Outlook
Markets Today
Recommended Reading






